Source: Eur Respir Rev 2006; 15: 51-57
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Decramer M.. Tiotropium as essential maintenance therapy in COPD. Eur Respir Rev 2006; 15: 51-57

Member's Comments

No comment yet.

Related content which might interest you: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Source: Eur Respir J 2002; 19: 209-216 Year: 2002 Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Source: Eur Respir J 2004; 23: 832-840 Year: 2004 Resistance to resistance Source: Annual Congress 2007 - Primary care: delivering the goods: "inhaled therapies" Year: 2007 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008 Exercise and dyspnoea in COPD Source: Eur Respir Rev 2006; 15: 72-79 Year: 2006 Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial Source: Eur Respir J 2010; 36: 65-73 Year: 2010 Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 639-644 Year: 2002 Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance Source: Eur Respir Rev 2006; 15: 37-41 Year: 2006 Long-term efficacy of repeated pulmonary rehabilitation programs (PRP) in chronic airway obstruction (CAO) Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Seasonal variations in exercise tolerance, activity and quality of life in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Source: Eur Respir J 2004; 23: 241-249 Year: 2004 Exacerbation and hospitalization in COPD patients with long-term high-intensity NPPV Source: Annual Congress 2007 - Technological progress in noninvasive ventilation Year: 2007 Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013